#United States #New York #Gross Law Firm #Soleno Therapeutics #DCCR

Soleno Therapeutics Investors Alert: Join the Class Action

Introduction
Shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) are facing a crucial time as The Gross Law Firm announces a class action lawsuit aimed at addressing potential losses experienced by investors. If you purchased shares within the specified class period, it's essential to understand your rights and the steps you can take to possibly recover your losses.

The Class Action Lawsuit
This lawsuit, as detailed by The Gross Law Firm, concerns allegations against Soleno Therapeutics for allegedly issuing misleading statements which downplayed significant safety concerns surrounding their product, diazoxide choline extended-release tablets, known as DCCR. The class period in question spans from March 26, 2025, to November 4, 2025.

During this period, multiple issues reportedly arose regarding the safety of DCCR especially concerning the risk of excess fluid retention in participants of the clinical trials. Investors have expressed concerns that these undisclosed risks were never accurately represented, leading to inflated stock values. As a result, shareholders might have endured losses once the truth about the product's viability and safety issues came to light.

Key Allegations
The lawsuit makes several serious allegations against Soleno Therapeutics, asserting that:
1. Inadequate Disclosure: The company's executives allegedly failed to disclose significant evidence of safety concerns related to DCCR during the clinical trial phases.
2. Misrepresentation: The product was misunderstood to pose lower safety risks than was actually the case, thus misleading investors about its commercial viability.
3. Reputational Fallout: Consequently, there appear to be risks involving greater patient discontinuation rates, reduced patient adoption, hesitancy among prescribers, regulatory repercussions, and potential legal consequences following commercialization.

Important Deadlines
If you are a shareholder who purchased shares during the class period, it's important to act quickly. Registration for participation in this class action is ongoing, but the deadline for considering a lead plaintiff role is May 5, 2026. Stakeholders are urged to begin the registration process here: Investor Registration Form.

Next Steps for Investors
Upon registering, investors will gain access to a dedicated portfolio monitoring service that will provide updates on the progression of the class action suit. Engaging in this lawsuit entails no cost or obligation for shareholders. Participation offers an opportunity for potential recovery if the lawsuit leads to favorable outcomes for the investors involved.

Why Choose The Gross Law Firm?
The Gross Law Firm is a well-established entity in the realm of class action litigation, renowned for advocating on behalf of investors who have been victims of deceptive practices in the market. Their commitment is to assist investors in navigating complex legal landscapes, particularly those affected by untruthful communications from public companies.

Contact Information
For more information, the Gross Law Firm encourages eligible shareholders to reach out:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018

Conclusion
Investors who traded Soleno Therapeutics shares during the class period should not overlook this lawsuit's implications. By understanding the complaint and the associated deadlines, you can take proactive steps in seeking potential restitution. Do not hesitate to seize this opportunity to protect your investment rights amid the ongoing legal proceedings.